Wire
B. Riley Adjusts Agenus Price Target to $14 From $8, Maintains Buy Rating
B. Riley Adjusts Agenus Price Target to $14 From $8, Maintains Buy Rating
$AGEN
$AGEN
2 stories mentioning AGENUpdated 10d ago
Every FINWIRES story that references AGEN, newest first.
Wire
Agenus Names BAP Pharma as Global Partner for Botensilimab Plus Balstilimab Access Programs
Agenus (AGEN) said Tuesday it appointed BAP Pharma as the company's global partner for botensilimab plus balstilimab authorized global access programs.These programs include France's Autorisation d'Acces Compassionnel pathway as well as paid named-patient programs in select countries outside the US. Under the arrangement, BAP Pharma will coordinate global access operations, including program requests, logistics, case coordination and related payment processing.Financial terms related to the collaboration were not disclosed.Shares of Agenus were down 7.7% in Tuesday trading.Price: $4.08, Change: $-0.34, Percent Change: -7.69%
$AGEN
